Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | ATF4 | P18848 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409024 | 0.86 | ATF4 (0.36) | DPP8DPP9GPR119ATF4GSK3B | |
| SCHEMBL22617462 | 0.85 | NR1H4 (0.38) | NR1H4ATF4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL22617353 | 0.83 | KCNQ3 (0.37) | NR1H4KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29495486 | 0.83 | KCNQ3 (0.37) | NR1H4KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29495535 | 0.82 | HPGDS (0.47) | DPP8DPP9NR1H4MLLT3MLLT1 | |
| SCHEMBL29495425 | 0.80 | GCGR (0.41) | GSK3BDYRK1A | |
| SCHEMBL29409132 | 0.79 | ATF4 (0.44) | GPR119ATF4 | |
| SCHEMBL29435971 | 0.77 | ATF4 (0.44) | DPP8DPP9ATF4GSK3BDYRK1A | |
| SCHEMBL27019009 | 0.73 | ATF4 (0.44) | NR1H4ATF4MLLT3MLLT1PRMT5 | |
| SCHEMBL24043473 | 0.72 | ATF4 (0.33) | NR1H4ATF4PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | DPP8 2699/4885DPP9 3893/4885GPR119 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.